M&A

Bidding war erupts for Shire as Takeda is stiff-armed on a $62.5B offer and Allergan jumps in

FDA, Regulatory

FDA’s insider review raises serious safety issues as Eli Lilly’s quick comeback shot for baricitinib heads for expert showdown

People, R&D

Novartis poaches Bristol-Myers/Amgen vet John Tsai for top drug development post in a $9B organization
More news caret

calendar Protocols

Quick hits from around the biopharma web

Apr 19

Tocagen licenses immunotherapy to ApolloBio for $16M upfront; WuXi AppTec unveils expanded lab testing site in New Jersey

Apr 18

Sanofi CFO Jerome Contamine hits the exit; Struggling Fibrocell triggers a strategic review

Apr 17

Novartis pledges $100M to malaria efforts; Lilly, Boehringer outlines new Jardiance kidney trial at Oxford

Apr 16

Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb

More Protocols caret

Dollar Premium

The 2-trial hurdle for drug approvals is steadily losing ground. Are we devaluing the industry's R&D gold standard?

Where does the science come from? The top 20 NIH-funded institutions in 2017

The good, the bad and the ugly for the top 15 spenders in the global drug R&D business: 2018

Bristol-Myers offers some eagerly awaited Checkmate-227 results, but they're not changing medical practice -- yet

What are the top 10 corporate VCs in biopharma today? And what do they want to fund — or steer clear of?

Where the money is: Top 100 VCs investing in US biotechs during 2017

twitter Marco

Hot BioTwitter bot - last updated ago

arrow-thick Most Viral

A Stunning Cure for One of the World's Most Devastating Blood Diseases

The New Yorker a day

Exclusive: Allergan in talks to acquire Shire, competing against...

Reuters Reuters Editorial a day

Selective RET Kinase Inhibition for Patients with RET- Altered Cancers | Annals of Oncology | Oxford Academic

OUP Academic a day

Novartis poaches Bristol-Myers/Amgen vet John Tsai for top drug development post in a $9B organization

ENDPOINTS NEWS John Carroll a day

Shire Rejects Takeda's $60 Billion Bid to Create Global Drug Giant

WSJ Noemie Bisserbe a day

Gene therapy could free some people from a lifetime of blood transfusions

MIT Technology Review Emily Mullin a day

Kleiner Perkins' Beth Seidenberg bumps Tmunity's cell therapy round to a cool $135M

ENDPOINTS NEWS John Carroll a day

Opioid Prescriptions Dropped In Every State Last Year

Forbes a day

Takeda makes Shire takeover proposal at about 46.50 pounds a share...

U.K. a day

P&G acquires Merck's consumer health business for about $4.21 billion

Reuters Reuters Editorial a day

timer Latest

Xconomy

Xconomy: Agenda Posted for Xconomy's What's Hot in Boston Biotech on May 16

NASDAQ

MorphoSys AG American Depositary Shares (MOR) Real-Time Stock Quote - NASDAQ.com

CNBC

Takeda in talks with Shire after $61 billion bid rejected

Reuters

Exclusive: Allergan in talks to acquire Shire, competing against...

ENDPOINTS NEWS

Biotech unicorn's 'brain' attracts a $115M mega-round as investors embrace AI upstart

ENDPOINTS NEWS

Bidding war erupts for Shire as Takeda is stiff-armed on a $62.5B offer and Allergan jumps in

Sciencedaily

Two is better than one to improve brain function in Alzheimer's disease mouse model

WSJ

Shire Rejects Takeda's $60 Billion Bid to Create Global Drug Giant

Bloomberg

Shire Rejects Takeda Pharmaceutical's $60 Billion Takeover Bid

OUP Academic

Selective RET Kinase Inhibition for Patients with RET- Altered Cancers | Annals of Oncology | Oxford Academic

fire Hot This Week

1

PR Newswire

Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors

2

FDA

FDA Briefing Document: Peripheral and Central Nervous System Drugs Advisory Committee Meeting - NDA 210365 Cannabidiol

3

CNBC

Amazon has shelved a plan to sell drugs to hospitals, and insiders say there are two reasons why

4

Abstracts Online

CT098 / 19 - Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)

5

Forbes

Inspired By A Health Scare, A 32-Year-Old's Startup Sells For $275 Million

6

Abstracts Online

CT078 - Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568

7

Forbes

Adding Merck's Keytruda To Chemo Halves Death Risk For Lung Cancer Patients

8

The New Yorker

A Stunning Cure for One of the World's Most Devastating Blood Diseases

9

Shire

Shire Announces Sale of Oncology Business to Servier for $2.4 Billion

10

BusinessWire

Checkmate Pharmaceuticals Presents Clinical Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting

Contact Endpoints News

You can also contact John Carroll, Editor at john@endpointsnews.com

← Go back
Thank you for staying with us. It's great to have you on board!
Aww, shucks. Perhaps you can tell us what we could do to make you interested in subscribing?
← Go back